// App-Quantinova.ai

: Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study

Researchers

Presenter

  • Heinz Wiendl

Principal Investigators

  • Klaus Schmierer

  • Suzanne Hodgkinson

  • Tobias Derfuss

  • Andrew Chan

  • Finn Sellebjerg

  • Anat Achiron

  • Xavier Montalban

  • Alexandre Prat

  • Nicola De Stefano

  • Frederik Barkhof

  • Letizia Leocani

  • Patrick Vermersch

  • Anita Chudecka

  • Sanjeev Roy

  • Ursula Boschert

Medical Centers

  • Department of Neurology, Institute of Translational Neurology, University of Münster

  • Blizard Institute, Centre for Neuroscience, Barts and The London School of Medicine & Dentistry, Queen Mary University of London

  • Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UNITED KINGDOM

  • Ingham Institute for Applied Medical Research, University of New South Wales Medicine

  • Department of Rheumatology, Odense University Hospital, Odense

  • University Hospital of Berne, University of Berne

  • Danish MS Center, Department of Neurology, University of Copenhagen, Rigshospitalet

  • Multiple Sclerosis Center, Sheba Academic Medical Center

  • Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, SPAIN

  • Département de Neurosciences, Université de Montréal

  • Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

  • Image Analysis Center, VU University Medical Center

  • UCL Institute of Neurology, London, UK

  • Experimental Neurophysiology Unit, Vita-Salute San Raffaele University

  • University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent

  • Cytel Inc

  • Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany

  • Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved